One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Health in the USA: under examination and under repair
The Lancet
doi : 10.1016/S0140-6736(21)00348-2
VOLUME 397, ISSUE 10275, P641, FEBRUARY 20, 2021
Sputnik V COVID-19 vaccine candidate appears safe and effective
Ian Jones,Polly Roy
doi : 10.1016/S0140-6736(21)00191-4
VOLUME 397, ISSUE 10275, P642-643, FEBRUARY 20, 2021
Next-generation COVID-19 vaccines: here come the proteins
Anna K Blakney,Paul F McKay
doi : 10.1016/S0140-6736(21)00258-0
VOLUME 397, ISSUE 10275, P643-645, FEBRUARY 20, 2021
Cabozantinib: a new first-line option for papillary renal cell carcinoma?
Delphine Borchiellini,Philippe Barthélémy
doi : 10.1016/S0140-6736(21)00316-0
VOLUME 397, ISSUE 10275, P645-647, FEBRUARY 20, 2021
US health and health care are a mess: now what?
David Blumenthal,Margaret Hamburg
doi : 10.1016/S0140-6736(21)00318-4
VOLUME 397, ISSUE 10275, P647-648, FEBRUARY 20, 2021
COVID-19 and the moral imagination
Mahomed Said Patel,Christine Beatrice Phillips
doi : 10.1016/S0140-6736(21)00151-3
VOLUME 397, ISSUE 10275, P648-650, FEBRUARY 20, 2021
COVID-19, structural racism, and migrant health in Canada
Germaine Tuyisenge,Shira M Goldenberg
doi : 10.1016/S0140-6736(21)00215-4
VOLUME 397, ISSUE 10275, P650-652, FEBRUARY 20, 2021
Value from health data: European opportunity to catalyse progress in digital health
Effy Vayena
doi : 10.1016/S0140-6736(21)00203-8
VOLUME 397, ISSUE 10275, P652-653, FEBRUARY 20, 2021
Offline: What is the UK for?
Richard Horton
doi : 10.1016/S0140-6736(21)00431-1
VOLUME 397, ISSUE 10275, P654, FEBRUARY 20, 2021
von der Leyen admits to COVID-19 vaccine failures
Rob Hyde
doi : 10.1016/S0140-6736(21)00428-1
VOLUME 397, ISSUE 10275, P655-656, FEBRUARY 20, 2021
Severe mental illness: reassessing COVID-19 vaccine priorities
Nayanah Siva
doi : 10.1016/S0140-6736(21)00429-3
VOLUME 397, ISSUE 10275, P657, FEBRUARY 20, 2021
Research Focus: The Cleveland Clinic at 100
Talha Burki
doi : 10.1016/S0140-6736(21)00430-X
VOLUME 397, ISSUE 10275, P658, FEBRUARY 20, 2021
Sharrelle Barber: at the intersection of place, race, and health
Pamela Das
doi : 10.1016/S0140-6736(21)00365-2
VOLUME 397, ISSUE 10275, P659, FEBRUARY 20, 2021
Healthy because you deserve it, unhealthy because you don't?
Michael Marmot
doi : 10.1016/S0140-6736(21)00366-4
VOLUME 397, ISSUE 10275, P660-661, FEBRUARY 20, 2021
Elizabeth Blackwell: breaching the barriers for women in medicine
Wendy Moore
doi : 10.1016/S0140-6736(21)00260-9
VOLUME 397, ISSUE 10275, P662-663, FEBRUARY 20, 2021
Gordon John McVie
Geoff Watts
doi : 10.1016/S0140-6736(21)00368-8
VOLUME 397, ISSUE 10275, P664, FEBRUARY 20, 2021
The Health Index for England
Jonathan Pearson-Stuttard,Sally C Davies
doi : 10.1016/S0140-6736(21)00201-4
VOLUME 397, ISSUE 10275, P665, FEBRUARY 20, 2021
Global need: including rehabilitation in health system strengthening
Tiago S Jesus,Michel D Landry
doi : 10.1016/S0140-6736(21)00207-5
VOLUME 397, ISSUE 10275, P665-666, FEBRUARY 20, 2021
Why the global health community should support the EndSARS movement in Nigeria
Nnenaya A Mmonu,Angela Aifah,Deborah Onakomaiya,Gbenga Ogedegbe
doi : 10.1016/S0140-6736(21)00194-X
VOLUME 397, ISSUE 10275, P666-667, FEBRUARY 20, 2021
A COVID-19 jab in the right direction
A Mark Clarfield,Karl Skorecki,Orly Manor,Shimon Glick
doi : 10.1016/S0140-6736(21)00310-X
VOLUME 397, ISSUE 10275, P667-668, FEBRUARY 20, 2021
Iron deficiency in PREVENTT
Bernd Froessler,Elizabeth Murphy,Nicolette Hodyl
doi : 10.1016/S0140-6736(21)00227-0
VOLUME 397, ISSUE 10275, P668, FEBRUARY 20, 2021
Iron deficiency in PREVENTT
Axel Hofmann,Irwin Gross,Domenico Girelli,Matti Aapro,Donat R Spahn
doi : 10.1016/S0140-6736(21)00226-9
VOLUME 397, ISSUE 10275, P668-669, FEBRUARY 20, 2021
Iron deficiency in PREVENTT
Anastazia Keegan,Philip Crispin,Amanda Ormerod,Kristen Brown,Christine Akers,Fiona King
doi : 10.1016/S0140-6736(21)00216-6
VOLUME 397, ISSUE 10275, P669, FEBRUARY 20, 2021
Iron deficiency in PREVENTT – Authors' reply
Toby Richards,Ben Clevenger,Darren Dahly,Martin Besser
doi : 10.1016/S0140-6736(21)00214-2
VOLUME 397, ISSUE 10275, P670, FEBRUARY 20, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00369-X
VOLUME 397, ISSUE 10275, P670, FEBRUARY 20, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00398-6
VOLUME 397, ISSUE 10275, P670, FEBRUARY 20, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00387-1
VOLUME 397, ISSUE 10275, P670, FEBRUARY 20, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00386-X
VOLUME 397, ISSUE 10275, P670, FEBRUARY 20, 2021
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y Logunov,Inna V Dolzhikova,Dmitry V Shcheblyakov,Amir I Tukhvatulin,Olga V Zubkova,Alina S Dzharullaeva,Anna V Kovyrshina,Nadezhda L Lubenets,Daria M Grousova,Alina S Erokhova,Andrei G Botikov,Fatima M Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I Zrelkin,Daria V Voronina,Dmitry N Shcherbinin,Alexander S Semikhin,Yana V Simakova,Elizaveta A Tokarskaya,Daria A Egorova,Maksim M Shmarov,Natalia A Nikitenko,Vladimir A Gushchin,Elena A Smolyarchuk,Sergey K Zyryanov,Sergei V Borisevich,Boris S Naroditsky,Alexander L Gintsburgand the Gam-COVID-Vac Vaccine Trial Group
doi : 10.1016/S0140-6736(21)00234-8
VOLUME 397, ISSUE 10275, P671-681, FEBRUARY 20, 2021
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
Peter Richmond,Lara Hatchuel,Min Dong,Brenda Ma,Branda Hu,Igor Smolenov,Ping Li,Peng Liang,Htay Htay Han,Joshua Liang,Ralf Clemens
doi : 10.1016/S0140-6736(21)00241-5
VOLUME 397, ISSUE 10275, P682-694, FEBRUARY 20, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K Pal,Catherine Tangen,Ian M Thompson Jr,Naomi Balzer-Haas,Daniel J George,Daniel Y C Heng,Brian Shuch,Mark Stein,Maria Tretiakova,Peter Humphrey,Adebowale Adeniran,Vivek Narayan,Georg A Bjarnason,Ulka Vaishampayan,Ajjai Alva,Tian Zhang,Scott Cole,Melissa Plets,John Wright,Primo N Lara Jr
doi : 10.1016/S0140-6736(21)00152-5
VOLUME 397, ISSUE 10275, P695-703, FEBRUARY 20, 2021
MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, with the MET kinase inhibitors cabozantinib, crizotinib, and savolitinib for treatment of patients with PRCC.
Amiodarone and hypothyroidism
Grigorios Christidis,Frank Lammert,Marcin Krawczyk
doi : 10.1016/S0140-6736(21)00204-X
VOLUME 397, ISSUE 10275, P704, FEBRUARY 20, 2021
Public policy and health in the Trump era
Steffie Woolhandler,David U Himmelstein,Sameer Ahmed,Zinzi Bailey,Mary T Bassett,Michael Bird,Jacob Bor,David Bor,Olveen Carrasquillo,Merlin Chowkwanyun,Samuel L Dickman,Samantha Fisher,Adam Gaffney,Sandro Galea,Richard N Gottfried,Kevin Grumbach,Gordon Guyatt,Helena Hansen,Philip J Landrigan,Michael Lighty,Martin McKee,Danny McCormick,Alecia McGregor,Reza Mirza,Juliana E Morris,Joia S Mukherjee,Marion Nestle,Linda Prine,Altaf Saadi,Davida Schiff,Martin Shapiro,Lello Tesema,Atheendar Venkataramani
doi : 10.1016/S0140-6736(20)32545-9
VOLUME 397, ISSUE 10275, P705-753, FEBRUARY 20, 2021
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi,Anna Balato,Charlotta Enerb?ck,Robert Sabat
doi : 10.1016/S0140-6736(21)00184-7
VOLUME 397, ISSUE 10275, P754-766, FEBRUARY 20, 2021
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by WHO as one of the most serious non-infectious diseases, psoriasis affects 2–3% of the global population. Mechanistically, psoriatic lesions result from hyperproliferation and disturbed differentiation of epidermal keratinocytes that are provoked by immune mediators of the IL-23 and IL-17 pathway. Translational immunology has had impressive success in understanding and controlling psoriasis. Psoriasis is the first disease to have been successfully treated with therapeutics that directly block the action of the cytokines of this pathway; in fact, therapeutics that specifically target IL-23, IL-17, and IL-17RA are approved for clinical use and show excellent efficacy. Furthermore, inhibitors of IL-23 and IL-17 intracellular signalling, such as TYK2 or ROR?t, are in clinical development. Although therapies that target the IL-23 and IL-17 pathway also improve psoriatic arthritis symptoms, their effects on long-term disease modification and psoriasis-associated comorbidities still need to be explored.
